Ironwood Pharma (IRWD) Reports Q1 Lost Per Share of 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update
May 5, 2015 4:02 PM EDTLINZESS® (linaclotide) U.S. net sales of $95.5 million in first quarter 2015
Total LINZESS prescriptions increased approximately 90% in first quarter 2015 compared to first quarter 2014
Reported positive top-line data from IW-3718 Phase IIa study for refractory GERD
Advanced sGC platform with initiation of first candidate, IW-1973, into Phase I study
Established agreement with Exact Sciences to co-promote Cologuard®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
